RCUS earnings date and last-quarter result: last quarter beat, P/E -9.46. Updated 2026-07-23.
Arcus Biosciences (RCUS) Research Hub
Arcus Biosciences (RCUS) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 17.76 USD (-4.21%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.46, market cap 2.93B. This hub links to the full technical, earnings and options research available for RCUS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 17.76 USD (-4.21%) |
| 52-week range | 17.43 USD – 31.74 USD |
| Trend regime | Range |
| 14-day RSI | 24 (Oversold) |
| Trailing P/E | -9.46 |
| Market cap | 2.93B |
| Dividend yield | 0.00% |
Available research for RCUS
Covered Call on RCUS: how it works, illustrative setup around the real 17.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RCUS: how it works, illustrative setup around the real 17.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RCUS: how it works, illustrative setup around the real 17.76 USD price, max profit/loss, breakeven and when to use it. Educational.
RCUS technical analysis: range, last 17.76 USD, RSI 24, 52w range 17.43 USD–31.74 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RCUS in?
Arcus Biosciences (RCUS) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is RCUS in an uptrend or downtrend?
As of 2026-10-26, RCUS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RCUS's trailing P/E ratio?
RCUS's trailing P/E is -9.46, with a market cap of 2.93B. See the earnings research page for full valuation detail.